According to Zacks Research, Bruker Co. (NASDAQ:BRKR) to earn $2.30 per share in fiscal year 2022.

In research made public on Tuesday, Nov. 22, Zacks Research raised its earnings forecasts for Bruker Corporation (NASDAQ:BRKR) for fiscal year 2022. Zacks Research analyst I. Bandyopadhyay predicts the medical research company will earn $2.30 per share in 2018, up from the previous forecast of $2.29 per share. The most recent projections for Bruker’s annual earnings put the company’s share price at $2.30. Bruker’s earnings per share are estimated at $0.70 in Q4 2022, $0.51 per share in Q2 2023, $0.64 per share in Q3 2023, $0.73 per share in the fourth quarter of 2023, $2.45 per share for the full year 2023, $0.66 per share in the first quarter of 2024 and $0.63 per share in the second quarter of 2024. Share of Bruker is expected to reach $0.73 in the fourth quarter.

On Wednesday, Bruker shares opened at $68.31. The share price currently has a P/E ratio of 37.33, a PEG ratio of 1.67 and a beta value of 1.21. The market capitalization of the stock is $10.05 billion. The current ratio is 2.36, the quick ratio is 1.49 and the debt-to-equity ratio is 1.20. All three ratios are in the same range. The company’s 50-day moving average is $58.89 and its 200-day moving average is $60.63. Bruker’s 52-week low is $48.42 and its 52-week high is $87.22.
BRKR has become the focus of attention from several ancillary equity analysts in recent months. StockNews.com gave Bruker’s stock a “strong buy” rating in a research note published Nov. 7. Previously, the stock had received a “Buy” rating. On Friday, October 21, a research note was published by UBS Group announcing that they have taken over the hedging on Bruker shares. They recommended “buying” the stock and set a price target of $70.00. Cowen lowered their price target for Bruker stock to $75.00 per share in a research note released Nov. 16. Citigroup raised their price target for Bruker shares from $70.00 to $80.00 and upgraded the stock from a “neutral” rating to a “buy” rating in a research report published Monday, Aug. 22.
Last but not least, in a research note published on Friday, November 4, TheStreet upgraded Bruker’s stock from a “c+” to a rating of “b-“. One stock research expert recommends selling the stock, three recommend buying it, and one recommending buying strongly. According to data from Bloomberg, the average recommendation for Bruker is a “Moderate Buy” and the price target is $74.00.
In recent months, BRKR has witnessed position shifts from several hedge funds alongside other institutional investors. During the first three months of the year, Trust Financial Corporation spent approximately $306,000 to acquire a new investment in Bruker. The Arizona State Retirement System increased Bruker’s ownership percentage by 0.9% in the first quarter. The Arizona State Retirement System now owns 28,696 shares of the medical research business after purchasing an additional 243 shares during the most recent quarter. The current market value of these shares is $1,845,000. During the first three months of the year, Stephens Inc. AR owns the percentage of Bruker shares at 24.1%. Following further purchases in the most recent quarter, Stephens Inc. (AR) now owns 3,310 shares of the medical research firm’s stock, valued at $213,000. The percentage of Bruker shares that Advisor Group Holdings Inc. property, rose 10.8 percentage points in the first quarter. Following an additional purchase of 3,458 shares in the prior quarter, Advisor Group Holdings Inc. now 35,569 shares of the medical research company, which it acquired for a total consideration of $1,294,000.
Last but not least, the National Bank of Canada Financial Institution increased its stake in Bruker by 2,181.0% during the first three months of the year. National Bank of Canada FI now owns 7,322 shares of the medical research company’s stock, valued at $458,000, after acquiring an additional 7,001 shares during the most recent quarter. This comes after the institution acquired 7,322 shares in the previous quarter. Currently, institutional investors and hedge funds own 69.64% of the company’s shares.

In addition, the company has announced a quarterly dividend, which will be paid to shareholders on December 16. On December 1, shareholders registered to receive dividends will receive $0.05 per share. This equates to a dividend payment of $0.20 per year and a dividend yield of 0.29%. The date that constitutes the ex-dividend date for this dividend is November 30. Bruker has a payout ratio of 10.93%.

Scientific instruments and analytical and diagnostic solutions are developed, manufactured and sold by Bruker Corporation. These products allow customers to examine life and materials at the microscopic, molecular and cellular level. The Life Science business of Bruker Scientific Instruments (BSI), the BSI Nano business, the Bruker Energy business and the Supercon Technologies business are the four business segments (BEST).

Leave a Comment